Biblio
Management of Patients undergoing CAR-T cell therapy in Germany. Oncol Res Treat. 2024.
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023;16(1):88.
Cellular therapy in lymphoma. Hematol Oncol. 2023.
Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023;11(8).
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.
Leukemic Stem Cells as a Target for Eliminating Acute Myeloid Leukemia: Gaps in Translational Research. Crit Rev Oncol Hematol. 2022:103710.
.